In recent years, we have witnessed the emergence of frameworks in support of the use of RWE. While it is not always specified how RWE was considered, there is a clear tendency of accepting RWE albeit not on all areas. Health Technology Assessment (HTA) is a multidisciplinary and systematic evaluation of health technologies and interventions accounting for both direct and indirect consequences. HTA bodies worldwide recognize the importance of real-world evidence (RWE) in addressing uncertainties around the effectiveness of new drugs at time of launch and in reassessments. NICE (55%), HAS (41%), AOTMiT (39%), IQWiG (35%) and FIMEA (32%) are the 5 HTA bodies who referenced the most RWE in their HTAs.

In this webinar, we will explore how to go from guidelines to real-world impact. We will take the example from the UK’s National Institute for Health and Care Excellence (NICE) ‘s real world evidence framework, which was published in 2021. From guidelines, we will look at how these guidelines are used by Market access and HEOR practitioners to establish methodology and limitations.

This webinar is intended for pharma and biotech companies, as well as academics who are interested in furthering their understanding of how real-world evidence can be used in the HTA process. It will explore:
– The NICE RWE Framework
– The differences between RWE and HTA in academia and industry
– Case studies
– Key challenges and limitations